Soligenix
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 15
- Market Cap
- $8.8M
- Website
- http://www.soligenix.com
- Introduction
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
- Conditions
- Mycosis FungoidesCutaneous T Cell LymphomaCTCL/ Mycosis FungoidesCTCL
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 80
- Registration Number
- NCT06470451
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
Dusquetide for the Treatment of Behcet's Disease
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 25
- Registration Number
- NCT06386744
- Locations
- 🇹🇷
Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 10
- Registration Number
- NCT06149247
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
Topical SGX302 for Mild-to-Moderate Psoriasis
- Conditions
- Plaque PsoriasisPsoriasisPsoriasis Vulgaris
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 47
- Registration Number
- NCT05442190
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 9
- Registration Number
- NCT05380635
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
- Prev
- 1
- 2
- 3
- Next
News
Soligenix Completes Manufacturing Transfer of Synthetic Hypericin for Rare Skin Cancer Treatment
Soligenix successfully transferred manufacturing of synthetic hypericin from Europe to the U.S. through partnership with Sterling Pharma Solutions, establishing scalable cGMP production for clinical trials.
HyBryte Shows Sustained Improvement in CTCL Lesions Post-Treatment
Soligenix's HyBryte demonstrated continued improvement in cutaneous T-cell lymphoma (CTCL) lesions even after treatment cessation.
Soligenix's HyBryte Enrolls First Patients in Phase 3 CTCL Trial
Soligenix initiates patient enrollment for the confirmatory Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphoma (CTCL).
Soligenix Forms European Medical Advisory Board for HyBryte CTCL Trial
Soligenix has established a European Medical Advisory Board (MAB) to guide its Phase 3 trial of HyBryte™ for cutaneous T-cell lymphoma (CTCL).
Soligenix Establishes European Medical Advisory Board for HyBryte™ CTCL Phase 3 Trial
Soligenix has formed a European Medical Advisory Board (MAB) to guide the Phase 3 trial of HyBryte™ for cutaneous T-cell lymphoma (CTCL).
Soligenix Launches Phase 2 Trial of SGX945 (Dusquetide) for Behçet's Disease
Soligenix has initiated a Phase 2 clinical trial to evaluate SGX945 (dusquetide) for treating aphthous ulcers associated with Behçet's Disease, a chronic auto-immune condition.
Soligenix Launches Phase 2 Trial of SGX945 (Dusquetide) for Behçet's Disease
Soligenix has initiated a Phase 2 clinical trial to evaluate SGX945 (dusquetide) for treating aphthous ulcers associated with Behçet's Disease.
Soligenix Initiates Phase 2 Trial of SGX945 (Dusquetide) for Behçet's Disease
Soligenix has commenced patient enrollment in a Phase 2 clinical trial to evaluate SGX945 (dusquetide) for the treatment of Behçet's Disease.
Soligenix Initiates Phase 2 Trial of Dusquetide (SGX945) for Behçet's Disease
Soligenix has commenced patient enrollment in a Phase 2 clinical trial evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease.
Soligenix to Initiate Phase 3 Trial of HyBryte for Cutaneous T Cell Lymphoma
Soligenix is set to begin a Phase 3 trial (FLASH2) of HyBryte for cutaneous T cell lymphoma (CTCL) treatment before the end of 2024, mirroring the design of the previous FLASH trial.